Department of Medical Oncology. Catalan Institute of Oncology. Avda Gran via 199-203. L'Hospitalet, Barcelona, Spain.
Department of Medical Oncology. Catalan Institute of Oncology. Avda Gran via 199-203. L'Hospitalet, Barcelona, Spain; Clinical Research in Solid Tumors Group (CReST), OncoBell Program.Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
Lung Cancer. 2018 May;119:99-102. doi: 10.1016/j.lungcan.2018.03.014. Epub 2018 Mar 17.
We present a 45-year-old patient diagnosed with anaplastic lymphoma kinase (ALK)-rearranged metastatic lung cancer who developed grade 4 interstitial lung disease (ILD) while on crizotinib treatment and was lately treated with brigatinib with no reappearance of ILD. To our knowledge, this is the first case report of successful treatment with brigatinib after crizotinib-induced ILD. Even though ILD secondary to brigatinib has been reported in clinical trials, no pulmonary toxicity has been seen in our patient, suggesting no crosslink lung toxicity between crizotinib and brigatinib.
我们报告了一例 45 岁的患者，该患者被诊断患有间变性淋巴瘤激酶 (ALK)-重排转移性肺癌，在接受克唑替尼治疗时发生了 4 级间质性肺病 (ILD)，随后改用布加替尼治疗，ILD 未再出现。据我们所知，这是首例克唑替尼诱导的 ILD 后用布加替尼成功治疗的病例报告。尽管在临床试验中已经报道了布加替尼引起的ILD，但我们的患者并未出现肺毒性，提示克唑替尼和布加替尼之间没有交叉肺毒性。
